PMID- 31795359 OWN - NLM STAT- MEDLINE DCOM- 20200327 LR - 20200327 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 16 IP - 23 DP - 2019 Nov 29 TI - Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. LID - 10.3390/ijerph16234794 [doi] LID - 4794 AB - A combination of cytoreductive surgery, either primary (PCS) or interval (ICS), and chemotherapy with a platinum-paclitaxel regimen is the well-accepted treatment for advanced-stage epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), and primary peritoneal serous carcinoma (PPSC), but it is still uncertain whether a combination of dose-dense weekly paclitaxel and low-dose triweekly cisplatin is useful in the management of these patients. Therefore, we retrospectively evaluated the outcomes of women with advanced-stage EOC, FTC, and PPSC treated with PCS and subsequent dose-dense weekly paclitaxel (80 mg/m(2)) and low-dose triweekly cisplatin (20 mg/m(2)). Between January 2011 and December 2017, 32 women with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV EOC, FTC, or PPSC were enrolled. Optimal PCS was achieved in 63.5% of patients. The mean and median progression-free survival was 36.5 and 27.0 months, respectively (95% confidence interval (CI): 26.8-46.2 and 11.3-42.7 months, respectively). The mean overall survival was 56.0 months (95% CI: 43.9-68.1 months), and the median overall survival could not be obtained. The most common all-grade adverse events (AEs) were anemia (96.9%), neutropenia (50%), peripheral neuropathy (28.1%), nausea and vomiting (34.4%), and thrombocytopenia (15.6%). These AEs were predominantly grade 1/2, and only a few patients were complicated by grade 3/4 neutropenia (21.9%) and anemia (6.3%). A multivariate analysis indicated that only suboptimal PCS was significantly correlated with a worse prognosis, resulting in an 11.6-fold increase in the odds of disease progression. In conclusion, our data suggest that dose-dense weekly paclitaxel (80 mg/m(2)) combined with low-dose triweekly cisplatin (20 mg/m(2)) is a potentially effective and highly tolerable front-line treatment in advanced EOC, FTC, and PPSC. Randomized trials comparing the outcome of this regimen to other standard therapies for FIGO stage IIIC-IV EOC, FTC, and PPSC are warranted. FAU - Cheng, Min AU - Cheng M AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan. AD - Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan. FAU - Lee, Howard Hao AU - Lee HH AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan. AD - Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan. FAU - Chang, Wen-Hsun AU - Chang WH AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan. AD - Department of Nursing, Taipei Veterans General Hospital, Taipei 112, Taiwan. FAU - Lee, Na-Rong AU - Lee NR AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan. AD - Department of Nursing, Taipei Veterans General Hospital, Taipei 112, Taiwan. FAU - Huang, Hsin-Yi AU - Huang HY AD - Biostatics Task Force, Taipei Veterans General Hospital, Taipei 112, Taiwan. FAU - Chen, Yi-Jen AU - Chen YJ AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan. AD - Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan. AD - Institute of Clinical Medicine, National Yang-Ming University, Taipei 112, Taiwan. FAU - Horng, Huann-Cheng AU - Horng HC AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan. AD - Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan. FAU - Lee, Wen-Ling AU - Lee WL AD - Department of Medicine, Cheng-Hsin General Hospital, Taipei 112, Taiwan. AD - Department of Nursing, Oriental Institute of Technology, New Taipei City 220, Taiwan. FAU - Wang, Peng-Hui AU - Wang PH AUID- ORCID: 0000-0002-6048-8541 AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan. AD - Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan. AD - Institute of Clinical Medicine, National Yang-Ming University, Taipei 112, Taiwan. AD - Department of Medical Research, China Medical University Hospital, Taichung 440, Taiwan. AD - The Female Cancer Foundation, Taipei 104, Taiwan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191129 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (Antineoplastic Agents) RN - P88XT4IS4D (Paclitaxel) RN - Q20Q21Q62J (Cisplatin) RN - TP protocol SB - IM MH - Adult MH - Aged MH - Antineoplastic Agents/*pharmacology MH - Antineoplastic Combined Chemotherapy Protocols/*pharmacology MH - Cisplatin/pharmacology MH - Dose-Response Relationship, Drug MH - Fallopian Tube Neoplasms/*drug therapy MH - Female MH - Humans MH - Middle Aged MH - Ovarian Neoplasms/*drug therapy MH - Paclitaxel/pharmacology MH - Peritoneal Neoplasms/*drug therapy MH - Retrospective Studies MH - Time Factors PMC - PMC6926653 OTO - NOTNLM OT - FIGO stage IIIC-IV OT - dose-dense weekly paclitaxel OT - epithelial ovarian cancer OT - fallopian tube cancer OT - low-dose triweekly cisplatin OT - primary peritoneal serous carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2019/12/05 06:00 MHDA- 2020/03/28 06:00 PMCR- 2019/12/01 CRDT- 2019/12/05 06:00 PHST- 2019/11/12 00:00 [received] PHST- 2019/11/20 00:00 [revised] PHST- 2019/11/25 00:00 [accepted] PHST- 2019/12/05 06:00 [entrez] PHST- 2019/12/05 06:00 [pubmed] PHST- 2020/03/28 06:00 [medline] PHST- 2019/12/01 00:00 [pmc-release] AID - ijerph16234794 [pii] AID - ijerph-16-04794 [pii] AID - 10.3390/ijerph16234794 [doi] PST - epublish SO - Int J Environ Res Public Health. 2019 Nov 29;16(23):4794. doi: 10.3390/ijerph16234794.